Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrate, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive Compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoan, or inhibiting the growth of a fungus or protozoan. The fungus may be a Candida species, Sacchawmyces species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan mitochondrial phosphate carrier protein.

Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I).

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.

Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.

Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrate, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoan, or inhibiting the growth of a fungus or protozoan. The fungus may be a Candida species, Sacchawmyces species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan mitochondrial phosphate carrier protein.

Abstract: According to the embodiments described herein, a methods for inhibiting small ubiquitin-like modifier enzymes in a cell are provided. Such methods may include administering certain substituted pyrrolo[2,3-b]-quinoxalines to the cell. In some aspects, the small ubiquitin-like modifier enzyme is SUMO E1 or SUMO E2. In some aspects, the methods may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, methods for treating a cancer, degenerative diseases and viral infection are provided. Such methods may include administering an effective amount of a pharmaceutical composition to a subject having cancer. The pharmaceutical composition may include a small ubiquitin-like modifier inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.

Abstract: A computer enclosure includes a rear panel and a lifting member. An opening is defined in the rear panel. The lifting member is mounted to the rear panel. The lifting member includes a handle portion and a first mounting bracket connected to the handle portion. The handle portion includes a lifting plate. The first mounting bracket includes a first rear mounting portion mounted to the rear panel. The lifting plate is accessible through the opening from an outside of the rear panel.

Abstract: A mounting apparatus includes a first bracket and a second bracket. Two guides are located on the first bracket. A locking block is located on the first bracket between the two guides. The second bracket receives a first fan. Two sliding portions are located on the second bracket and engaged with the two guides. A latch is resiliently deformable and located on the second bracket between the two sliding portions. A plurality of receiving holes is defined in the latch. The second bracket is slidable between the two guides relative to the first bracket. The locking block is can engage in the plurality of receiving holes to secure the first bracket to the second bracket in a plurality of positions.

Abstract: According to the embodiments described herein, a tricyclic SUMOylation inhibitor compound is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a SUMOylation inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.

Abstract: An electronic device includes a chassis and a bracket. An opening is defined in the chassis. The opening has a first side edge and a second side edge located at opposite sides thereof. A length of the second side edge is greater than that of the first side edge. The bracket is mounted in the opening. The bracket includes a pair of first hooks and a pair of second hooks at opposite sides thereof. A distance between the pair of first hooks corresponds to the length of the first side edge. A distance between the pair of second hooks corresponds to the length of the second side edge. The pair of first hooks is engaged into the opening along the first side edge. The pair of second hooks is engaged into the opening along the second side edge.

Abstract: An electronic device enclosure includes an enclosure body, a bezel, a resilient locking clip, and an unlocking clip. An opening is defined in the enclosure body. The bezel assembly is mounted to the enclosure body and covers the opening. The resilient locking clip is attached to the enclosure body. A protrusion is located on the resilient clip. The unlocking clip is attached to the bezel assembly and is operable along a first direction. The unlocking clip is capable of being rotated from a first position to a second position. In the first position, the resilient locking clip blocks the bezel assembly from moving along the first direction. In the second position, the resilient clip is disengaged from the bezel by the unlocking clip.

Abstract: An electronic device includes a chassis and a bracket. An opening is defined in the chassis. The opening has a first side edge and a second side edge located at opposite sides thereof. A length of the second side edge is greater than that of the first side edge. The bracket is mounted in the opening. The bracket includes a pair of first hooks and a pair of second hooks at opposite sides thereof. A distance between the pair of first hooks corresponds to the length of the first side edge. A distance between the pair of second hooks corresponds to the length of the second side edge. The pair of first hooks is engaged into the opening along the first side edge. The pair of second hooks is engaged into the opening along the second side edge.

Abstract: A mounting apparatus includes a first bracket and a second bracket. Two guides are located on the first bracket. A locking block is located on the first bracket between the two guides. The second bracket receives a first fan. Two sliding portions are located on the second bracket and engaged with the two guides. A latch is resiliently deformable and located on the second bracket between the two sliding portions. A plurality of receiving holes is defined in the latch. The second bracket is slidable between the two guides relative to the first bracket. The locking block is can engage in the plurality of receiving holes to secure the first bracket to the second bracket in a plurality of positions.